Sylvester Comprehensive Cancer Center

Breast Cancer Program

Program Leader(s)

Description of the Program

The Breast Cancer Program comprises the activities of investigators who share common scientific interests and goals and participate in competitively funded research. The Braman Family Breast Cancer Institute (BFBCI) Breast Cancer Program at the Sylvester Comprehensive Cancer Center (Sylvester) brings together a highly interactive group of investigators whose molecular research is directed to a better understanding of the mechanisms underlying breast cancer development and progression; aiming to develop new means of prevention, diagnosis, and treatment, with the ultimate goal of improving breast cancer survival. The Program Co-Leaders, Joyce Slingerland and Marc Lippman are both clinician-scientists with longstanding experience in basic, translational and applied research in the breast cancer field.

Goals of the Program

The ultimate goal of the Breast Cancer Program is to improve survival rates, and decrease morbidity and mortality for breast cancer patients by improving therapeutic options and fostering the translation of scientific inquiry in focused molecular biologic areas.

The specific program research goals of the Breast Program (BrCa) include:

  1. To delineate molecular pathways underlying breast cancer development and progression
  2. To develop new models for the study of breast cancer
  3. To identify and validate novel therapeutic targets and bring these to clinical trials for patient care

To achieve these goals, the program scientific investigations include the following:

  • Investigation of the signal transduction pathways responsible for breast cancer cell proliferation, morphology and metastasis leading to the identification and validation of novel molecular markers
  • Discovery, development and design of biological and experimental drug therapies that will aid in treating anti-estrogen resistant breast cancer
  • Molecular discoveries that bridge the bench to the clinic and foster the translation of molecular strategies to generate new treatment options
  • Prognostication of, and to develop better therapeutic options for breast cancer patients

Participants

E-mail a Friend